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ABSTRACT
Inflammatory bowel diseases (IBD) include ulcerative colitis
(UC) and Crohn’s disease (CD) and are due to a dysregulation
of the antimicrobial defense normally provided by the intes-
tinal mucosa. This inflammatory process may extend outside
the bowel to many organs and also to the respiratory tract.
The respiratory involvement in IBD may be completely
asymptomatic and detected only at lung function assess-
ment, or it may present as bronchial disease or lung
parenchymal alterations. Corticosteroids, both systemic and
aerosolized, are the mainstay of the therapeutical approach,
while antibiotics must be also administered in the case of
infectious and suppurative processes, whose sequels some-
times require surgical intervention. The relatively high inci-
dence of bronchopulmonary complications in IBD suggests
the need for a careful investigation of these patients in order
to detect a possible respiratory involvement, even when they
are asymptomatic. 
Keywords: Crohn’s disease, inflammatory bowel disease, respi-
ratory involvement, ulcerative colitis.
RIASSUNTO 
Le IBD (inflammatory bowel diseases) includono la colite ul-
cerosa (UC) e il morbo di Crohn (CD), causate da un’alterazio-
ne della difesa antimicrobica normalmente esercitata dalla
mucosa gastroenterica. Questo processo infiammatorio può
estendersi al di fuori dell’intestino in altri organi e anche al-
l’apparato respiratorio. Il coinvolgimento respiratorio nelle
IBD può essere del tutto asintomatico e rilevabile solo all’esa-
me della funzionalità respiratoria, oppure manifestarsi con
sintomi di patologia delle vie aeree o del parenchima polmo-
nare. I corticosteroidi, sia per via sistemica che inalatoria, so-
no il caposaldo della terapia, mentre anche gli antibiotici deb-
bono essere somministrati nelle forme infettive e con ampia
componente suppurativa, i cui reliquati talvolta richiedono un
approccio chirurgico. La relativamente elevata incidenza di
complicazioni broncopolmonari nelle IBD suggerisce la neces-
sità di un’accurata valutazione di questi pazienti per rivelare
un eventuale coinvolgimento respiratorio, anche in assenza di
sintomi.
Parole chiave: Coinvolgimento respiratorio, colite ulcerosa,
malattie infiammatorie intestinali, morbo di Crohn. 
Definition and pathogenesis of IBD
Ulcerative colitis (UC) and Crohn's disease (CD) are
usually referred to with the common label of
inflammatory bowel diseases (IBD) due to their simi-
lar inflammatory nature and unknown cause.
However, many differences in the clinical and
pathologic features of these two chronic intestinal
diseases have been found. Ulcerative colitis
involves the rectum and may affect part or all of
colon, and the inflammation is typically restricted
to the mucosa. Crohn's disease, on the other hand,
is generally limited to the ileum and colon, not
rarely in a patchy manner, and the inflammation is
mostly transmural, with consequent stenosis and
fistulae. 
IBD result from an impaired barrier function of the
intestinal mucosa characterized by increased per-
meability and defective regulation of tight junctions
[1]. The failure of this barrier, determining an expo-
sition to fecal antigens, may induce an inappropri-
ate activation of the acquired mucosal immune sys-
tem [2]. As a matter of fact, antibodies against intes-
tinal bacteria are frequently detected in serum of
patients with IBD [3] but, although many pathogens
have been incriminated, none has been demonstrat-
ed to play a causative role [4,5]. The initial fast,
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2 generic response to intestinal microbes is supplied
by the innate immune system, while the adaptive
immune system recognizes individual bacteria
through antigen-specific receptors. 
A number of inflammatory cells and mediators and
genetic alterations involved in the pathogenesis of
IBD have been identified in recent years [5]. The
Th1 cytokines interleukin (IL)-12, interferon-γ, and
tumor necrosis factor (TNF)-α are the main media-
tors of inflammation found in CD [6], whereas in
UC an increased expression of Th2 cytokine IL-5 is
often seen. Elevated levels of IL-23 and Th17
cytokines have been found in both CD and UC [7].
As to the innate immune system, genetic factors
play an important role in the development of IBD,
particularly in CD. In this respect, the first identified
locus is located at the chromosome position 16q12
[8,9] and the different genes included within this
locus are named NOD2. The NOD2 system
encodes an intracellular sensor of peptidoglycan (a
component of bacterial cell wall) and activates
components of the innate immune system. The stim-
ulation of the NOD2 leads to the production of
cytokines and antimicrobial peptides, and an
impaired response at this level is now recognized as
the likely cause of IBD [10,11]. In fact, in healthy
subjects NOD2, primed by microbial peptidogly-
cans, activates nuclear factor(NF)-κB, which in turn
enhances the production of antibacterial cytokines.
However, the acute stimulation of NOD2 by bacte-
rial peptidoglycans is also modulated by inhibitory
cytokines, like transforming growth factor (TGF)-β
and IL-10, which downregulate the proinflammatory
cytokines, and this downregulation is impaired in
subjects with IBD, who are thus exposed to a chron-
ic intestinal inflammation. Three NOD2 polymor-
phisms have been seen in about 30% of European
patients, each impairing responses to peptidogly-
cans. Carriers of a NOD2 polymorphism are more
likely than non carriers to have an ileal involvement
[12]. Homozygosis for a polymorphism confers a
much greater risk of CD [13]. In addition,
autophagy, a mechanism aimed to clear microbes,
and its gene ATG16L1, are involved in CD [14],
where abnormal Paneth-cell morphology has also
been found [15]. The autophagy is implicated in T-
cell tolerance; thus in IBD an increased susceptibil-
ity to intestinal inflammation occurs, due to defects
in T-cell tolerance [16,17].
Incidence of respiratory diseases (RD) in IBD and of
IBD in RD
Respiratory diseases are a possible complication of
IBD, even if pulmonary alterations are often over-
looked, especially when respiratory symptoms are
already present before the diagnosis of IBD. The first
recognition of a correlation between the diseases of
the two districts is attributable to Kraft [18], who in
1976 reported a series of patients with unexplained
bronchial suppuration. Since then, numerous
reports have outlined the association between IBD
and respiratory pathologies. The rate of extra-intesti-
nal manifestations in patients with IBD ranges from
21 to 41% [19,20], increasing with the duration of
the intestinal disease, and being greater in CD than
in UC [21]. However, the true prevalence of lung
involvement in IBD remains unknown and it seems
rather variable, because in some series only few
cases of respiratory complications have been found.
In fact, in 624 patients [22] no respiratory compli-
cation was reported, and only 3/1400 cases of IBD
were found by Rodgers et al. (0.4%) [23]. On the
other hand, it can be difficult to establish a relation-
ship between IBD and RD in patients who are
already affected with pulmonary disease at the
diagnosis of IBD, or are current smokers.
Respiratory diseases occurring in IBD may consist
merely in a subclinical abnormal lung function or,
in contrast, they may manifest as clear interstitial
lung disease [19]. An ongoing bowel inflammation
is not a prerequisite for the onset of respiratory alter-
ations, since bronchopulmonary diseases that
developed after colectomy have been reported [24].
The respiratory changes can occur at any time in the
history of IBD, but they generally follow it by a time
interval varying from days to decades [25]. 
Concerning the “respiratory dysfunction in asymp-
tomatic patients”, Mohamed-Hussein et al. [26]
reported that 57.6% of their patients with UC had at
least one abnormal lung function test (PFT) result:
restrictive dysfunction in 30.7% and obstructive in
11.5%. The impairment of PFT was more pro-
nounced and significant in patients with active UC
than in controls or in patients with the inactive
form. In a review including over 600 patients with
UC, more than 50% of patients showed abnormal
PFT results when compared to healthy controls, and
the decrease in diffusion capacity of the lung for
carbon monoxide (DLCO) was the most common
defect [19]. The impairment of pulmonary function
has been observed also in children. Munck et al.
[27] first reported a series of 26 children with CD in
acute or quiescent phase, all non-smokers and
asymptomatic. Ten of them were studied before the
start of therapy so as to exclude possible influence
of therapy itself on the respiratory abnormalities.
During the remission the value of DLCO resulted
higher than during the acute phase (p < 0.0001)
even if 50% of patients still presented an abnormal
DLCO. With the aim of investigating possible differ-
ences in respiratory function abnormalities between
the two IBD identities, Tzanakis et al. [28] studied
132 patients (47 CD and 85 UC). An increased,
though not significant, percentage of abnormal PFT
results among both patient groups was observed
compared to controls. A statistically significant dif-
ference was found only for the DLCO decrease in CD
patients when compared to controls (p < 0.05), and
a slightly greater, but significant, reduction of DLCO
in the active compared to the inactive CD and UC.
In a study of 66 IBD patients (35 CD and 31 UC),
Herrlinger et al. [29] found 42% with at least one
abnormal pulmonary function test compared to 3%
of controls, and with no significant difference
between both diseases. The forced expiratory vol-
ume in one second (FEV1) and the inspiratory vital
capacity (IVC) resulted significantly dependent on
the disease activity, whereas the DLCO was not.
None of the patients complained of pulmonary
symptoms. Douglas et al. [30] and Bonnier et al.
[31] found no correlation between DLCO reduction
and disease activity or severity of IBD. Dierkes-
Globisch and Mohr [32] investigated 44 IBD
patients without pulmonary symptoms, 20% of
whom showed an obstructive or restrictive ventila-
tory defect compared to 5% of controls (p < 0.05%),
but with no correlation to activity and duration of
bowel disease or to smoking habit. 
From all these reports it seems clear that the pul-
monary involvement in IBD is more frequent than
believed, has no clear relationship with the activity
of the intestinal disease and often is asymptomatic
and detectable only at the lung function investiga-
tion. This is further supported by the finding by
Wallaert et al. of a high proportion of latent lym-
phocytic pulmonary alveolitis in the bronchoalveo-
lar lavage (BAL) of 18 consecutive patients with CD,
all free from respiratory symptoms and showing a
normal chest X-ray [33]. In fact, an abnormal per-
centage of alveolar lymphocytes was observed in
11 of 18 patients (61%) with a T-lymphocyte preva-
lence. The same was found by Sarioglou et al. at the
BAL fluid examination, where a lymphocytic alve-
olitis was evident in 46.6% of IBD cases [34]. 
A number of clinical lung diseases can be found in
the course of IBD, but the true frequency of these
conditions is unknown [19], although it has been
shown that the incidence is higher in patients with
UC than in those with CD (35). Respiratory diseases
in patients affected by IBD can be classified as “air-
ways disease”: tracheobronchial stenosis,
bronchiectasis, chronic bronchial suppuration,
chronic bronchitis, COPD, asthma and bronchioli-
tis; “parenchymal disease”: cryptogenic organizing
pneumonia (COP), interstitial lung disease, local-
ized interstitial fibrosis, necrotic nodule and
eosinophilic pneumonitis; “pleural effusions” are
uncommon as a manifestation of IBD (Table I). 
According to Black et al. [36], who report 171 res-
piratory pathologies in 155 patients, the “large air-
ways” are the most common site of involvement in
IBD, accounting for 39% of all cases, and
bronchiectasis was present in 66% of these cases.
The second most frequently reported respiratory
disease in IBD patients is chronic bronchitis [37],
detected in a surprisingly high proportion (81%) of
nonsmoker patients [36]. This led the authors [36]
to affirm that in these patients the bronchial inflam-
mation is mainly caused by a diffusion of the bowel
inflammatory condition to the bronchial tree. These
results confirm the previous findings of Camus et al.
[35] where 15/33 patients (45.4%) with IBD had
large airways involvement, six of them (40%) in the
form of bronchiectasis; 9 of the 15 cases were post-
colectomy. Bronchiectasis was also the predomi-
nant finding in the report of Spira et al. [38] regard-
ing 7 patients with IBD and large airways involve-
ment, where three of them developed respiratory
symptoms in 1-4 months after colectomy. Finally,
Kelly et al. [39], in a retrospective analysis of
patients with IBD and respiratory manifestations,
identified 10 patients with bronchiectasis, 8 of
whom post colectomy. These authors also reported
that bronchiectasis in IBD patients is more severe,
more rapidly progressive and more responsive to
steroids than in non IBD patients. Moreover, since
colectomy has no effect on the respiratory involve-
ment, they formulated the hypothesis that the dis-
continuation of anti-inflammatory drugs after the
surgical resection of an intestinal tract is probably
able to uncover or worsen the pulmonary manifes-
tations. 
The involvement of the “small airways” in IBD, con-
sidered rare in both entities, has proved more fre-
quent than was supposed in the days before expira-
tory high resolution computed tomography (HRCT)
of the chest was introduced. This imaging tool has
allowed the detection of the small airways involve-
ment in these patients, some of whom also with
normal PFT results. In like manner, Songur et al.
[40] examined with PFT and inspiratory and expira-
tory HRCT 36 patients with IBD (23 UC and 13 CD,
only one with CD a current smoker), and 14 healthy
non-smokers, free from respiratory symptoms.
Nineteen (53%) patients had HRCT abnormalities,
with features suggestive of air trapping in expiratory
CT scan in 12 (33%) patients, 6 of whom were
symptomatic. No significant correlation was found
between HRCT abnormalities and PFT results,
whereas there was a difference between the two




















• Necrobiotic pulmonary nodules
Drug-induced pneumonitis
Definition of abbreviations: BHR, bronchial hyperresponsiveness;
COP, cryptogenic organizing pneumonia; COPD, chronic obstructive
pulmonary disease; DLCO, diffusion capacity of the lung for carbon













































2 types of IBD as to the incidence of CT abnormali-
ties, that was 92% in CD and 39% in UC. Tzakanis
et al. [41] investigated the function of small airways
using the density dependence of airflow technique
in 30 patients with IBD (18 UC and 12 CD) and 16
healthy subjects. They found that both groups of
patients with IBD had an increased volume of
isoflow (Viso V˙) despite their normal baseline spiro-
metric values. The average Viso V˙ was lower in
active vs. inactive UC (p < 0.05), while there was no
difference between the two forms of IBD. The mean
value of Viso V˙ in untreated patients was significant-
ly greater than in control subjects (p < 0.05). 
“Bronchiolitis” is the most commonly reported dis-
ease involving the small airways in patients with
IBD, and it is frequently associated with peribron-
chiolar granuloma [36,42-46]. Camus et al. [35]
reported two cases diagnosed with this pathological
manifestation among 33 patients. They were young
men affected by UC, in an inactive phase in one
case, who complained of productive cough, and
showed diffuse small opacities at chest x-ray and an
obstructive pattern at PFT. In this patient the open
lung biopsy revealed fibrosing and stenosing bron-
chiolitis and inflammatory lesions. Both Vandenplas
et al. [43] and Trow et al. [47] reported one case
each of granulomatous bronchiolitis in women with
CD who had undergone bowel resection. The respi-
ratory alteration presented with nonproductive
cough and progressive dyspnea, and chest pain was
also reported by Vandenplas' patient. In both cases
the CT of the chest demonstrated irregularly dis-
persed micronodular densities, and the lung biopsy
revealed an infiltrate of mononuclear cells associat-
ed with non-necrotizing epithelioid granulomas
and giant cells in the bronchiolar walls. A
CD4+:CD8+ cell ratio of 3:1 in BAL was found in the
first patient, whereas in the second patient there
was a peribronchial lymphocytic infiltrate and poor-
ly organized granuloma with a normal BAL
CD4+:CD8+ ratio.
Sometimes patients complaining of symptoms due
to bronchiolitis may erroneously be thought to be
affected with asthma, as reported by Bentur et al.
[48] in a 13-year-old girl with CD since 8 years of
age. The repeated episodes of shortness of breath,
which started at age 9 years in this patient, had
been interpreted as asthma. CT scan of the chest
revealed irregularly diffused ground glass, and lung
biopsy showed bronchiolitis obliterans and
mononuclear inflammation with noncaseating
granulomas, not related to sulfasalazine, because
the pulmonary status did not improve when sul-
fasalazine was stopped. 
Also the incidence of “asthma” is far more frequent
than previously considered and the disease has a
more severe course in IBD patients. A prevalence of
7.1-7.8% is reported by Bernstein et al. [49], with a
higher percentage in women [19].
The airway inflammation sometimes may not be
detectable by routine PFT and only an asympto-
matic increase in bronchial hyperresponsiveness
(BHR) [50] together with high IgE levels may be
found during the chronic bowel inflammation
despite the absence of atopic symptoms [51,52].
Mansi et al. [53] studied 14 CD children without
extraintestinal manifestations, 5 of whom in a phase
of clinical remission, with the aim to evaluate the
bronchial responsiveness to methacholine in com-
parison with 10 healthy nonatopic subjects and 10
with mild bronchial asthma. In patients with CD,
BHR was present in a very high proportion (71% of
cases) even in the absence of clinical and function-
al evidence of airways disease. The dose of bron-
choconstrictor agent causing a 20% reduction of
FEV1 compared to baseline (PD20) was not related
either to the baseline FEV1 or to total blood
eosinophil count or serum IgE levels; however the
PD20 values found in these patients were higher
than those seen in asthmatic individuals. BHR was
evident both in atopic patients with CD and in 7 of
the 10 nonatopic CD subjects. The higher preva-
lence of BHR reported in this study than in others
[50] may likely depend on the different mean age of
the study group and this accords with the observa-
tion that BHR progressively decreases with age
[54]. BHR was found in several studies with an inci-
dence ranging from 17 to 45% [50,55]. In a study
comparing 30 IBD patients with 16 controls without
gastrointestinal disease the respiratory and allergic
symptoms were more prevalent in IBD patients 
(p < 0.04 and p < 0.007 respectively) than in the con-
trols, and particularly in UC patients (p < 0.004).
Abnormal PFTs were present in 27% of patients 
(p < 0.04 vs. controls) and BHR in 17%. Skin prick
tests were positive in 50% IBD but no difference
was found between the two IBD subgroups. In 4 of
the patients the PD20 value of methacholine (MCh)
test was < 16 mg/ml, while negative in all control
subjects, and this hyperreactivity index was unrelat-
ed to the activity of the intestinal disease [55].
Bartholo et al. [56] found a greater (p = 0.026) pos-
itivity with methacholine challenge in 15 patients
with CD than in 20 healthy controls, and a higher
(p = 0.011) level of lymphocytes in induced spu-
tum. These results strengthen the possibility that a
subclinical inflammation in absence of pulmonary
symptoms can occur. Ceyan et al. [55] demonstrat-
ed a higher prevalence of positive skin-prick tests 
(p < 0.02) and increased allergic symptoms 
(p < 0.007) among 30 patients with IBD (19 UC and
11 CD) compared to 16 controls without gastroin-
testinal disease.
Alterations affecting the “lung parenchyma” are rel-
atively rare in IBD patients, and cryptogenic organ-
izing pneumonia (COP) is the most common report-
ed manifestation [35]. 
Pathogenesis of respiratory complications in IBD
The current pathogenetic hypothesis of IBD is an
impairment of the mucosal immune regulation of
the gastrointestinal system concerning intraluminal
bacterial antigens in genetically predisposed per-
sons [57]. As a matter of fact, antibodies against
intestinal bacteria are frequently detected in serum
















Saccharomyces cerevisiae antibodies to baker's
yeast have been seen in CD patients [58]. One
hypothesis to explain the respiratory involvement in
IBD is that these products cross-react with common
antigens outside the bowel in the human body.
Furthermore, a common embryologic origin of both
gastrointestinal and bronchial tree may support the
onset of inflammation at two different sites with
common embryological origin. Respiratory symp-
toms may also be due to an aberrant homing of
inflammatory cells to the lungs from the primary
site of chronic inflammation [59], and this might
also explain why the large airways disease is fre-
quently not cured by colectomy [38]. Thus, accord-
ing to this hypothesis, the inflammatory process
would shift from the gastrointestinal tract to the air-
ways [60].
A recent study has shown that patients with CD
have increased pulmonary permeability which
appears unrelated to the disease activity [61]. The
same conclusions were reached by Gursoy et al.
[62] in their study on UC patients without respirato-
ry symptoms, who underwent technetium-99m
aerosol scintigraphy. The increase in permeability
might even provide a satisfactory explanation for
the occurrence of bronchial hyperresponsiveness
(BHR) [53].
It should also be taken into account that not rarely
the side effects of treatments may be a cause of pul-
monary disease in IBD patients [63], in the form of
hypersensitivity reactions and pulmonary edema
[64-66]. Usually, most reactions related to sul-
fasalazine and 5-ASA are seen between 2 and 6
months after commencement of drug administra-
tion [19]. Also a relapse or onset of pulmonary
tuberculosis may be caused by the immunosuppres-
sant monoclonal antibodies and other anti-inflam-
matory drugs used to control the chronic intestinal
inflammatory process [67-69].
Clinical manifestations and treatment of RD in IBD
The involvement of the airways in the course of IBD
may manifest itself with persistent productive
cough, exertional dyspnea, obstructive and/or
restrictive ventilatory deficit with or without abnor-
mal chest radiograph. Interestingly, a severe tra-
cheobronchial stenosis has been reported [70] in a
young patient with CD. His respiratory symptoms
developed two years after colectomy, with a pro-
ductive cough initially controlled by beclometha-
sone. However, ten years later there was an
increase in the volume of sputum with purulent fea-
tures and fever, and a CT scan of the chest showed
a marked distortion of the large bronchi with
mucoid impaction in the small bronchi and alveolar
micronodules. Fiberoptic bronchoscopy (FOB)
revealed mucosal inflammation, purulent secretions
and tracheal and bronchial deformities, with a
severe stenosis of both mainstem bronchi, and
marked airflow obstruction at the PFT. The patient
was initially treated with antibiotics and oral
steroids, tapered over a period of 13 months. After
12 months CT and FOB appeared unchanged, but
no mucosal inflammation was present, and symp-
toms had disappeared at six weeks following the
start of therapy; an improvement on PFT was meas-
ured at 28 months of switch therapy with inhaled
budesonide. This case probably represents an
advanced stage of tracheo-bronchial involvement
which had developed over a long period of time. 
Symptoms due to bronchiectasis and chronic bron-
chitis are the most frequent clinical presentation of
airways pathology in IBD, generally following the
onset of bowel disease and sometimes after the
colectomy (71). Also in the series reported by Kelly
et al. [39], 80% of IBD patients with bronchiectasis
developed their symptoms after surgery for IBD,
supporting Kinnear's and Higenbottam's hypothesis
that inflammatory process may shift from the bowel
to the airway [60] and manifest or increase after the
bowel inflammation has been eliminated [39]. In a
series collected by Higenbottam et al. [72], ten
patients with UC, all non smokers, presented pro-
ductive cough. Six out of these had normal chest
radiograph and three a minor obstructive ventilato-
ry defect on PFT. In one of these patients broncho -
graphy revealed the presence of bronchiectasis. The
remaining 4 patients developed a marked exertion-
al dyspnea and bilateral pulmonary shadows on the
chest X-ray with a mixed ventilatory defect. There
was no correlation with sulfasalazine therapy and
in 3 patients the symptoms began after colectomy.
In 7 patients the symptoms were relieved by inhaled
beclomethasone.
However the presence of respiratory symptoms may
be highly variable in IBD patients and completely
absent in those with milder disease. In fact, HRCT
performed in 17 IBD patients (3 out of 17 were CD
patients) revealed bronchiectasis in 13 (76%), in the
absence of sputum production in those with a lesser
extent of bronchial alteration, while 9 patients pre-
sented signs of air trapping, and 5 a "tree in bud"
pattern at CT [73]. 
As regards asthma symptoms, Bernstein et al. [74]
report an increased risk for this disease in either
form of IBD in a population-based study screening
for a number of other chronic inflammations.
Asthma was the second most common extraintesti-
nal comorbidity, after arthritis, without significant
differences in relation to the type of IBD and gen-
der, although a slightly greater prevalence in
women was present [19].
Sometimes patients complain of dyspnea on exer-
tion or even at rest, nonproductive cough, fever and
general malaise due to the involvement of lung
parenchyma in the form of interstitial and alveolar
diffuse changes. In these cases it is necessary to dis-
tinguish the alterations directly consequent to the
bowel disease from those caused by adverse reac-
tions to the drugs used for IBD. Alterations of the
lung parenchyma are more frequent in UC and in
females, cryptogenic organizing pneumonia (COP)
being the most reported single case [36]. In most
patients [21,35,75-78] COP generally follows the
onset of IBD, and it presents with fever, dyspnea,






























2 Areas of peribronchiolar inflammation and fibrosis
and/or fibrosis of the peribronchial region [24] or
subpleural opacities [78] have been seen on CT
scan, with a tendency to migrate and consolidate
[77]. At physical examination of the chest, inspira-
tory crackles are found on both sides of the chest,
and pulmonary function tests show a restrictive pat-
tern. The culture of bronchoalveolar lavage fluid
generally does not lead to the growth of bacteria,
acid-fast bacilli or fungi, and the cytologic study
shows an increased percentage of lymphocytes with
a variable, although usually normal, CD4/CD8
ratio. A normal CD4/CD8 ratio is reported by Simon
[77], whereas Carratù [78] found it increased. In
this case an open-lung biopsy revealed isolated foci
of non-specific chronic inflammation, myofibro -
blastic proliferation and peripheral endoalveolar
foamy macrophages. Rarely, cases of pulmonary
infiltrates and eosinophilia have been reported both
before and during or after the diagnosis of IBD [35].
Dry cough was the only symptom referred by a 38-
year-old woman affected by CD and treated with
mesalazine [79]. Chest x-ray showed some alveolar
opacities in the right middle lobe, that were inter-
preted as pneumonitis and successfully treated with
antimicrobial drugs. However the pulmonary infil-
trates relapsed despite the intense antibiotic therapy
previously adopted. BAL was performed and the
cellular examination revealed a marked increase
(30%) in eosinophilis. At surgical biopsy a pattern
of interstitial fibrosis with few non-caseating epithe-
lioid granulomas was demonstrated, together with
sparse lesions of bronchiolitis obliterans and
desquamative interstitial pneumonia. This was the
first description of a necrobiotic pulmonary nodule
associated with interstitial pneumonia and
eosinophilia. However, the hypothesis – albeit
unlikely - that mesalazine treatment was responsi-
ble was difficult to confirm or exclude because,
while the first pneumonia resolved without the
withdrawl of the drug, the relapse improved after
corticosteroid therapy and discontinuation of treat-
ment with 5-ASA. 
As to the pulmonary complications derived from
the use of drugs for IBD, sulfasalazine was first pre-
scribed in the management of these chronic bowel
diseases in the 1940s [80]. It is a compound of 
sulfapyridine linked to 5-ASA (mesalazine) [19]. It is
known that the drug may have clinically important
side-effects, including pulmonary toxicity [80]. In
this respect, a retrospective study on published
reports between 1972 and 1999 [80] revealed that
lung toxicity caused by sulfasalazine is more com-
mon in ulcerative colitis, where it mainly manifests
with dyspnea (80% of cases), fever (70%) and
cough (64%). Peripheral eosinophilia was reported
in 52% of cases. Interestingly, the respiratory func-
tion assessment showed abnormalities in 28 out of
29 tests performed, consisting in a restrictive defect
in 66% of cases. Chest radiography was abnormal
in all cases, showing mainly pulmonary infiltrates,
that were confirmed at CT scan, where it revealed
typical infiltrates, ground glass opacities, and pul-
monary nodules with central cavitation. BAL was
performed in 11 patients, with 5 (45.4%) demon-
strating an increase in eosinophils ranging from 23
to 69%. Based on the histological findings, the final
diagnosis was eosinophilic pneumonia in 11 cases,
and in 4 fibrosing alveolitis. Other less common
histological diagnoses included COP, desquamative
interstitial pneumonia (DIP) and less specified
pneumopathies, like sulfasalazine lung disease or
pulmonary hypersensitivity reaction. 
Averbuch et al. [81] reported a case of rash urticaria
and generalized angioedema in a 58-year-old man
suffering from UC and treated with sulfasalazine
therapy, where the adverse symptoms resolved with
the discontinuation of the drug. The patient under-
went a protocol of desensitization (gradually
increasing doses of sulfasalazine with progressive
tapering of prednisone), and after two months he
developed a dry cough, fever and progressive dys -
pnea. A chest X-ray showed diffuse bilateral intersti-
tial infiltrates which dramatically improved with
sulfasalazine discontinuation and administration of
high dose prednisone. In this case the first manifes-
tations may be interpreted as a typical allergic reac-
tion, whereas the parenchymal lung alterations like-
ly reflect a direct toxicity of the drug. Alternatively,
both features could be due to the same steroid-
responsive mechanism, but with higher doses of
prednisone necessary for the prevention of the inter-
stitial pneumonia. In a case of eosinophilic pneu-
monia in a 35-year-old woman treated with oral
mesalazine, who improved after discontinuation of
therapy, the lymphocyte stimulation test with the
drug was positive for mesalazine and negative for
sulfasalazine and sulphapyridine [65]. 
Only few cases [82,83] of pneumonitis have been
reported in patients treated with methotrexate for
IBD, whereas one series reported 70 cases of tuber-
culosis in IBD patients given therapy with inflix-
imab (anti-tumor necrosis factor monoclonal anti-
body) [84].
Inhaled steroids are very effective, also for the long
term control of the respiratory disease, in patients
with chronic bronchitis, in symptomatic asthmatic
patients, and in upper airways disease too [70].
Oral corticosteroids can improve interstitial disease
[35], COP [76,78], granulomatous bronchiolitis
[43], and drug-induced pneumonia [81], while
intravenous administration is the initial manage-
ment of life-threatening subglottis stenosis or exten-
sive interstitial lung disease [35]. A surgical
approach is sometimes necessary to repair the
sequels of destructive inflammatory processes, like
tracheal and bronchial stenosis. 
Causes of mortality in IBD
Despite the marked improvement in medical and
surgical therapy, it remains a debated issue whether
the death risk is greater in IBD patients compared to
the general population, also because dissimilar
results have been reported in many studies, where
the most severe patients, bearing the worse progno-
















malnutrition, infection, and side effects of medical
and surgical therapy may increase the fragility of
these patients. 
Cucino et al. [86], with the aim to analyze the
comorbidities possibly contributing to increased
mortality of patients with IBD, pooled the data from
6 consecutive years (1991-1996) and analyzed
them together. In patients affected with UC the
comorbidities were most frequently represented by
shock and protein/calorie malnutrition, volume
depletion and anemia, septicemia, and peritonitis,
whereas CD patients often showed nutritional, vol-
ume and electrolyte disturbances, besides surgical
complication and pulmonary insufficiency.
A meta-analysis was carried out to ascertain the
overall and cause-specific mortality in a cohort of
UC patients published in the literature from 1965 to
2006 [85]. Five Scandinavian studies included in
this meta-analysis reported higher mortality rates
(SMR 1.2, p = 0.001) than did non-Scandinavian
countries, similarly to an EC-IBD study (European
Collaborative group of Inflammatory Bowel
Disease) that reported a slightly higher mortality in
North Europe than in Southern Europe [87]. The
studies which presented SMRs stratified for age at
diagnosis did not show significant differences,
whereas those which considered the extent of UC at
diagnosis showed a higher SMR when the inflam-
mation was close to the rectum (1.2). Similarly, the
SMR was higher during the first 5 years after the
diagnosis (1.4) and especially during the first year
(2.2) (88). Lower SMR (0.8) was encountered in UC
patients who had not been given immunosuppres-
sive drugs (6-mercaptopurine, azathioprine or
infliximab) and in non-colectomized patients (0.9).
The mean percentage of deaths ascribed to UC was
17% (ranging from 11% to 30%), the most common
causes being colorectal cancer and surgical or post-
operative complications. Six out of ten series report-
ed SMRs for specific causes of deaths. A significant-
ly lower risk of dying from lung cancer was
observed (SMR 0.3, p = 0.04), whereas a greater,
but not significant, risk of dying from COPD (SMR
1.6, p = 0.26) and a significant risk for pneumonia
(SMR 3.1, p > 0.001) were found. Only one study
estimated the risk of dying from pulmonary
embolism, reporting a significantly higher SMR of
4.0. The lower SMR reported for lung cancer may
be due to the fact that UC patients often are non
smokers, so that the difference in smoking habits
between the UC patients and the healthy popula-
tion may act as a confounding factor. The other
reported causes of death include cardiovascular,
renal and liver diseases, leukemia and non-
Hodgkin's lymphoma.
The EC-IBD study [87] on mortality in UC in Europe
did not find a higher mortality risk in UC patients
compared with the normal population. The mortal-
ity was slightly higher in females than in males
(SMR 1.39 and 0.92 respectively) and slightly high-
er in older patients. A comparison of disease specif-
ic mortality between North European region and
South European region also revealed a higher SMR
only for pulmonary disease (SMR 1.19 and 0,82
respectively). 
Similarly, investigating the overall and cause-specif-
ic mortality in CD, Duricova et al. [89] examined
the results from nine studies, six of which also
reported cause-specific mortality. A slightly but sig-
nificantly increased pooled SMR (1.39) for mortality
in general was observed, with no significant gender
difference although it was higher in women, where-
as a higher significant SMR for mortality due to pul-
monary diseases was found in CD compared to the
general population and UC patients. In this meta-
analysis a significantly increased risk of death from
lung cancer was detected (SMR 2.72), as well as
from COPD (SMR 2.55), that led to a tendency of
risk of overall death from respiratory disease to be
increased (SMR 1.44). This can likely be explained
by a higher prevalence of smokers among CD
patients compared to the general population and to
UC patients, and it is known that smoking has detri-
mental effects on the clinical course of CD [90].
Another meta-analysis by Canavan et al. [91], per-
formed in the same type of patients, revealed higher
SMR in hospital and referral centers with respect to
community-based studies. 
CONCLUSIONS
In conclusion, the inflammatory process of IBD is
not necessarily restricted to the gastrointestinal
tract, since many studies have demonstrated that
latent or patent pulmonary involvement can occur
in these patients even in the complete absence of
symptoms [92]. The available diagnostic tools may
make us able to detect early IBD-related respiratory
syndromes.
A bronchial hyperresponsiveness in patients affect-
ed with UC or CD and no respiratory symptoms can
easily be detected by methacholine challenge, so
indicating that in the airways an inflammation not
detectable by routine PFTs may exist [53]. Use of
the density dependence of air-flow technique may
help to clarify if small airways are affected [41], and
a defect in the transfer of respiratory gases, as
expressed by the decrease in the DLCO, suggests the
presence of a process involving the interstitial pul-
monary district possibly not identifiable by standard
chest radiographs [27]. In this context, HRCT scan
obtained at full expiration is a valid tool to show air
trapping mainly in patients with emphysema [93],
asthma [94] and hypersensitivity pneumonia [95]
even in the absence of recognizable morphologic
abnormalities on inspiratory scans [40]. This
method can be useful to detect small airways
involvement also in asymptomatic IBD patients.
As previously reported, pulmonary involvement,
encountered in about 60% of IBD patients [96], can
range from a simple defect of pulmonary function
without symptoms to fibrosing alveolitis with a greater
risk of mortality. For this reason the early detection of
latent abnormalities of pulmonary function is impor-
tant to prevent future and more severe respiratory






























2 ranted in view of the fact that IBD-related respiratory
syndromes generally respond well to inhaled or sys-
temic corticosteroid treatment [25,35,70]. 
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